From: Long-term outcome of renal cell carcinoma in patients with HIV who undergo surgery
Feature | Total | HIV group | Control |
---|---|---|---|
N | 67 | 33 | 34 |
Age at surgery | 51 ± 11 | 51 ± 12 | 50 ± 11 |
BMI | 24.8 ± 2.6 | 24.4 ± 2.2 | 25.1 ± 2.9 |
Gender | Â | Â | Â |
Female/Male | 12/55 | 5/28 | 7/27 |
Creatinine | 81.4 ± 16.5 | 77.1 ± 18.8 | 85.7 ± 12.9 |
eGFR | 91.33 ± 17.29 | 94.69 ± 19.69 | 88.06 ± 14.15 |
CRP | 10.92 ± 2.67 | 7.45 ± 3.78 | 14.94 ± 30.05 |
Albumin | 42.5 ± 4.7 | 41.6 ± 4.8 | 43.4 ± 4.4 |
HGB (g/L) | 126.6 ± 21.6 | 113.6 ± 12.6 | 139.3 ± 20.8 |
Tumor Size | 4.42 ± 2.51 | 4.52 ± 2.95 | 4.33 ± 1.95 |
CD4 cell count(cell/) | 523.3 ± 223.1 | 401.7 ± 210.1 | 641.3 ± 166.2 |
CD4/CD8 ratio | 0.77 ± 0.37 | 0.68 ± 0.40 | 0.86 ± 0.33 |
Clinical Stage | Â | Â | Â |
 cT1 | 34 | 16 | 18 |
 cT2 | 25 | 13 | 12 |
 cT3 | 8 | 4 | 4 |
Pathological Stage | Â | Â | Â |
 pT1 | 46 | 24 | 21 |
 pT2 | 12 | 5 | 7 |
 pT3 | 10 | 4 | 6 |
Side | Â | Â | Â |
Left/Right | 43/24 | 19/14 | 24/10 |
GPS | Â | Â | Â |
 0 | 40 | 20 | 20 |
 1 | 24 | 11 | 13 |
 2 | 3 | 2 | 1 |
Histology, n (%) | Â | Â | Â |
 Clear cell tumor | 58 | 27 | 31 |
 Chromophobe cell tumor | 6 | 5 | 1 |
 Other | 3 | 1 | 2 |
Positive HBsAg, n (%) | 4 | 3 | 1 |
Positive anti-HCV Ab, n (%) | 3 | 1 | 2 |
CCI | 7.58 ± 1.75 | 6.85 ± 1.18 | 8.69 ± 1.93 |
Baseline ART regimen | Â | Â | Â |
PI-based regimen | 14 | 14 | - |
NNRTI-based regimen | 18 | 18 | - |
INSTI-based regimen | 1 | 1 | - |
Grade | Â | Â | Â |
 1 | 33 | 21 | 16 |
 2 | 24 | 8 | 13 |
 3 | 9 | 4 | 6 |
Surgical approach | Â | Â | Â |
 Partial resection | 20 | 7 | 13 |
 Radical nephrectomy | 47 | 26 | 21 |
Bleeding(mL) | 135.7 ± 77.4 | 114.0 ± 51.8 | 169.2 ± 98.5 |
Operating Time(h) | 1.3 ± 0.4 | 1.2 ± 0.4 | 1.4 ± 0.5 |
Length of stays | 11.7 ± 3.8 | 11.8 ± 3.8 | 11.6 ± 3.9 |
KPS | 90.3 ± 12.8 | 91.8 ± 13.1 | 88.8 ± 12.5 |
Leibovich Score 2003 | 1.22 ± 1.62(0–6) | 1.27 ± 1.62 | 1.18 ± 1.66 |